Floatz logo

9-valent human papillomavirus recombinant vaccine

Genital Wart

Xiamen UniversityvaccinePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Genital Wart cohort.

Asset / SponsorPhaseRating
9vhpv vaccine
Merck Sharp & Dohme LLC
Phase 3BB
v503
Merck Sharp & Dohme LLC
Phase 3BB
Tsc-204-C0702
TScan Therapeutics, Inc.
Phase 1CC
Tsc-204-A0201
TScan Therapeutics, Inc.
Phase 1CC
Tsc-201-B0702
TScan Therapeutics, Inc.
Phase 1CC

View all 9 →

Same molecule, other indications

9-valent human papillomavirus recombinant vaccine is also rated in:

anal canal carcinoma in situDormant
BB
Indicative ·
66 / 100
View asset →
prostate intraepithelial neoplasiaDormant
B
Indicative ·
60 / 100
View asset →
penile cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →